Spectranetics' (SPNC) AngioSculptX Receives CE Mark

August 10, 2016 9:01 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

The Spectranetics Corporation (Nasdaq: SPNC) announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a drug coating. It is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis.

"AngiosculptX represents a unique coronary scoring technology that incorporates a drug coating. Given its clinical results, it is a significant advancement in therapy options for patients," said Professor Bruno Scheller of Saarlandes University Clinic in Homburg, Germany.

"Spectranetics is committed to providing specialized and innovative tools alongside compelling clinical data to improve our patients’ quality of life, and AngioSculptX exemplifies these important elements,” said President and CEO Scott Drake.

As previously disclosed, and part of the original acquisition of AngioScore, Inc., there is a $5 million milestone payment related to receiving CE mark for AngioSculptX that the Company expects to pay in the third quarter.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Related Entities

Earnings, Definitive Agreement

Add Your Comment